SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of Nutex Health Inc. (NASDAQ: NUTX) (“Nutex” or the “Company”). The lawsuit seeks to recover losses on behalf of investors who purchased the Company’s securities between August 8, 2024 and August 14, 2025, inclusive (the “Class Period”). If you purchased Nutex securities and suffered losses, you have until October 21, 2025, to seek appointment as lead plaintiff. Inves ...

Core Viewpoint - Nutex Health Inc. is facing a securities fraud class action lawsuit, with allegations of materially false and misleading statements regarding its business and operations [3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of Texas on behalf of investors who purchased Nutex securities between August 8, 2024, and August 14, 2025 [3]. - The lawsuit alleges violations of the Securities Exchange Act of 1934 against Nutex and certain senior officers [3]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiffs must file papers by October 21, 2025 [4]. - Serving as a lead plaintiff is not required to share in any recovery, and all representation is on a contingency fee basis, meaning shareholders pay no fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for its clients since 1993 and has represented large public and private pension funds [5]. - The firm has been recognized multiple times in The National Law Journal's "Plaintiffs' Hot List" and has been listed in The Legal 500 for sixteen consecutive years [5].

Core Viewpoint - Nutex Health Inc. is facing allegations of issuing materially false and misleading statements during the class period from August 8, 2024, to August 14, 2025, which has led to a class action lawsuit against the company [1]. Group 1: Allegations and Issues - The complaint alleges that Nutex Health's third-party vendor, HaloMD, engaged in fraudulent activities to achieve favorable arbitration results, which inflated the company's revenues [1]. - It is claimed that the revenues from HaloMD's engagement in the IDR process were unsustainable due to the fraudulent nature of the conduct [1]. - The company allegedly overstated its ability to remediate material weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [1]. - Nutex is accused of misclassifying stock-based compensation obligations as equity instead of liabilities, increasing the risk of delays in filing financial reports with the SEC [1]. - The allegations suggest that Nutex's business and financial prospects were overstated, making the public statements by the defendants materially false and misleading [1]. Group 2: Class Action Details - Shareholders who purchased shares of Nutex Health during the specified class period are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for October 21, 2025 [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. - Participation in the case does not incur any cost or obligation for the shareholders [2].

Financial Performance - Nutex Health Inc. is expected to report a loss of $5.43 per share with projected revenue of approximately $221.9 million for the upcoming quarterly earnings release on October 1, 2025 [1][6] - The company has a price-to-earnings (P/E) ratio of 8.42, indicating how the market values its earnings [5][6] - Nutex's price-to-sales ratio is 0.91, suggesting that its stock trades at less than its annual sales [5] - The enterprise value to sales ratio is 1.32, indicating a valuation slightly above its sales when considering debt and cash [5] - A current ratio of 2.27 reflects good short-term financial health, with more than twice the current assets compared to liabilities [5] Legal Challenges - Nutex is facing legal challenges, including a class action lawsuit filed by Bronstein, Gewirtz & Grossman, LLC, alleging violations of federal securities laws [2] - Another class action lawsuit has been filed by Pomerantz LLP, seeking damages for alleged securities law violations [3] - Investors have until October 21, 2025, to request to be lead plaintiffs in the ongoing litigation [3] - Rosen Law Firm is advising Nutex investors to secure legal counsel before the October 21, 2025 deadline, highlighting potential eligibility for compensation without out-of-pocket expenses [4] Market Position - Nutex operates in the healthcare sector, providing innovative healthcare solutions and aims to differentiate itself through unique service offerings [1] - The company faces competition from other healthcare providers [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on October 21, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Nutex securities between August 8, 2024, and August 14, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [2]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. Group 2: Allegations Against Nutex - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices, including the involvement of HaloMD in fraudulent arbitration schemes [4]. - It is claimed that Nutex overstated its ability to remediate weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [4]. - The allegations suggest that these misrepresentations inflated Nutex's business and financial prospects, resulting in investor damages when the truth was revealed [4].

Accessibility StatementSkip Navigation NEW YORK, Sept. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Nutex Health Inc. ("Nutex Health Inc." or the "Company") (NASDAQ: NUTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Nutex Health Inc. investors who were adversely affected by alleged securities fraud between August 8, 2024 and August 14, 2025. Follow the link below to get more information and be contacted by a member of our t ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Nutex Health Inc. ("Nutex Health Inc." or the "Company") (NASDAQ: NUTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Nutex Health Inc. investors who were adversely affected by alleged securities fraud between August 8, 2024 and August 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/nutex- ...

LOS ANGELES--(BUSINESS WIRE)--Nutex Health Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – NUTX. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nutex Health Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Nutex securities is from August 8, 2024, to August 14, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by October 21, 2025, to serve as lead plaintiff [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3] Group 3: Case Allegations - The lawsuit alleges that Nutex made false and misleading statements regarding its financial practices and internal controls [4] - Specific claims include that Nutex engaged in fraudulent activities through a third-party vendor, HaloMD, which led to unsustainable revenue [4] - The allegations also state that Nutex overstated its ability to remediate internal control weaknesses and improperly classified stock-based compensation obligations [4]

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, alleging that these companies made materially false and misleading statements regarding their business operations and prospects [1]. Group 1: PubMatic, Inc. (NASDAQ: PUBM) - The class period for PubMatic is from February 27, 2025, to August 11, 2025, with a lead plaintiff deadline of October 20, 2025 [2]. - Allegations include failure to disclose a significant shift of clients to a new platform by a top DSP buyer, resulting in reduced ad spend and revenue for PubMatic [2]. - Defendants' positive statements about the company's business were deemed materially misleading and lacked a reasonable basis [2]. Group 2: Snap Inc. (NYSE: SNAP) - The class period for Snap is from April 29, 2025, to August 5, 2025, with a lead plaintiff deadline of October 20, 2025 [3]. - The complaint alleges that Snap's optimistic reports on advertising growth were misleading, as they relied too heavily on the company's execution capabilities [3]. - Defendants failed to disclose significant execution errors and macroeconomic challenges, leading to materially misleading statements about the company's prospects [3]. Group 3: Nutex Health Inc. (NASDAQ: NUTX) - The class period for Nutex is from August 8, 2024, to August 14, 2025, with a lead plaintiff deadline of October 21, 2025 [4]. - Allegations include engaging in a scheme to defraud insurance companies, leading to unsustainable revenue claims [4]. - The company overstated its ability to remediate internal control weaknesses, resulting in improper accounting of stock-based compensation obligations [4]. Group 4: C3.ai, Inc. (NYSE: AI) - The class period for C3.ai is from February 26, 2025, to August 8, 2025, with a lead plaintiff deadline of October 21, 2025 [6]. - The complaint alleges that the company's optimistic growth reports were misleading, relying heavily on the CEO's health and effectiveness [6]. - Defendants failed to disclose that the CEO had not sufficiently recovered to fulfill his role, leading to materially misleading statements about the company's prospects [6].